SARS-CoV-2 Mpro inhibitor ensitrelvir: asymmetrical cross-resistance with nirmatrelvir and emerging resistance hotspots

SARS-CoV-2 main protease (Mpro) inhibitors are the first-line COVID-19 treatment. Nirmatrelvir is used worldwide, while ensitrelvir, licensed in Japan and Singapore, has received FDA fast-track designation. To facilitate population monitoring for viral resistance and guide next-generation inhibitor...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Yuyong Zhou, Karen A. Gammeltoft, Helena D. Tjørnelund-Sjursen, Line A. Ryberg, Anna Offersgaard, Anna Czarnota, Zhe Duan, Long V. Pham, Ulrik Fahnøe, Günther H.J. Peters, Santseharay Ramirez, Jens Bukh, Judith M. Gottwein
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Taylor & Francis Group 2025-12-01
Reeks:	Emerging Microbes and Infections
Onderwerpen:	Antiviral resistance SARS-CoV-2 protease inhibitor ensitrelvir nirmatrelvir
Online toegang:	https://www.tandfonline.com/doi/10.1080/22221751.2025.2552716
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!